Pathological elucidation study using AMPA-PET and GABA-PET for patients with Angelman syndrome

Miyazaki Tomoyuki0 个研究点目标入组 10 人开始时间: 2021年8月19日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients who meet Williams clinical diagnostic criteria
•- Genetically confirmed Angelman syndrome (deletion, uniparental disomy, imprinted mutation, or UBE3A gene mutation)
•- Men and women between 20 and 50 years old at the time of registration
•- Patients who have given written consent to participate in this study.

•- Patients who have respiratory problems.
•- Patients who have an allergy to anesthetics.
•- Pregnant, lactating female.
•- Sensitive to alcohol
•- Implantation of metal substances and pacemakers
•- Head, neck and body size not suitable for MRI scanner
•- A tattoo larger than one point (including tattoo and art makeup)
•- A remarkable variant of brain structure (including congenital and traumatic)
•- Take Clonazepam, Clobazam
•- Patients who are taking benzodiazepine hypnotics and cannot stop the drug from a week before the [11C] Flumazenil test.
•- At the time of registration, any of the following laboratory test value abnormalities
•Serum creatinine 1.5 mg / dl or more
•AST 150 IU / L or more
•ALT 150 IU / L or more
•- Participating in unapproved nuclear medicine clinical trials and clinical trials within 6 months prior to enrollment
•- Patients judged as inappropriate for study by the research investigator

发起方

Miyazaki Tomoyuki